Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is the worst prognoses among all the malignancies. Now, gemcitabine (Gem) is the first line chemotherapeutic drug for advanced pancreatic cancer. However, Gem is usually ineffective to the PDAC because of high degree of drug resistance. Hypoxia and immune supp...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Zhao, Tiansuo, Ren, He, Jia, Li, Chen, Jing, Xin, Wen, Yan, Fan, Li, Jing, Wang, Xiuchao, Gao, Song, Qian, Dong, Huang, Chongbiao, Hao, Jihui
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2014
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4385849/
https://ncbi.nlm.nih.gov/pubmed/25544770
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak